Viatris Inc. (VTRS) exhibits 35.2% gross margins and -8.1% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.4% implied options volatility.
Sustained 35.2% gross profitability converts into -18.7% operating margin and -8.1% ROIC, outpacing sector cost of capital.
ROIC: -8.1% // GM: 35.2%YoY revenue trajectory of -3.0% paired with 8.78% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -3.0% // FCF YLD: 8.78%Altman Z-Score of 0.81 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.81 // F-SCORE: 6/9Trading at 24.0x trailing P/E (33.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.4% implied move with a 0.65 put/call ratio around $19.00 max pain.
IMPL MOVE: ±7.4% // P/C: 0.65Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -14.6% net margins.
NET MARGIN: -14.6% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for VTRS & activate live FRED threshold breach alerts.